Biomarker collection for Alzheimer's disease
Part of Mental health clinical trials.
This study collects blood and spinal fluid samples from adults who are being tested for Alzheimer's disease during a day hospital visit. The goal is to improve understanding of Alzheimer's biomarkers for better diagnosis and care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You are not under a legal guardianship.
- Your doctor has ordered blood tests and a spinal tap to check for Alzheimer's-related markers (beta-amyloid and tau protein).
- You agree to sign the consent form for this research.
- You have social security or health insurance (not state medical aid).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a simple blood test to quickly detect Alzheimer's-related brain changes (amyloid plaques). It may help people with memory concerns avoid a more invasive PET scan and get answers faster.
This study is testing whether a simple blood test can help diagnose Alzheimer's disease and predict how the disease will progress. If you have memory or thinking problems that have been getting worse, you may be able to join.
This study uses brain scans or spinal fluid tests to confirm Alzheimer's-related changes. It aims to track the disease over time to better understand and improve care.
This study looks at a specific brain pathway that may be linked to early memory loss in Alzheimer's disease. It compares people with early Alzheimer's to healthy older adults to understand how connections between brain cells start to break down.
This study looks at how to better predict and understand Alzheimer's disease by using advanced brain scans and spinal fluid tests. It aims to find ways to identify people who stay healthy longer despite risk factors.
This study is testing whether blood-based markers can help identify Alzheimer's disease earlier. It is for people with Alzheimer's, mild memory problems, or no memory issues at all.
Hear when a new Neurocognitive Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.